Nitazoxanide: Indications and Dosing
Nitazoxanide is FDA-approved for treating diarrhea caused by Giardia lamblia and Cryptosporidium parvum in immunocompetent patients, with age-specific dosing for 3 days, but has limited efficacy in HIV-infected and immunocompromised individuals. 1
FDA-Approved Indications
Nitazoxanide is approved for:
- Giardiasis (Giardia lamblia)
- Cryptosporidiosis (Cryptosporidium parvum)
Both indications apply to patients ≥1 year of age 1
Dosing Regimens
Pediatric Dosing (1-11 years)
Use oral suspension only - tablets contain too much drug for this age group 1:
- Ages 1-3 years: 100 mg (5 mL suspension) orally every 12 hours with food for 3 days 1, 2
- Ages 4-11 years: 200 mg (10 mL suspension) orally every 12 hours with food for 3 days 1, 2
Adolescent and Adult Dosing (≥12 years)
- 500 mg tablet orally every 12 hours with food for 3 days 1
- Alternative: 500 mg (25 mL suspension) orally every 12 hours with food for 3 days 1
Critical administration requirement: Must be taken with food 1
Efficacy Data
Giardiasis
Nitazoxanide demonstrates excellent efficacy in immunocompetent patients:
- Adults/adolescents: 85-100% clinical response rate vs. 30-44% with placebo 1
- Children: 85% clinical response (comparable to 80% with metronidazole) 1, 3
- Most patients resolve diarrhea within 3-4 days 4, 5
Cryptosporidiosis
Efficacy varies significantly by immune status:
Immunocompetent patients:
- Adults/adolescents: 87-96% clinical response vs. 41% with placebo 1, 4, 6
- Children: 80% clinical response vs. 41% with placebo 4
HIV-infected/immunocompromised patients:
- Significantly reduced efficacy - the drug was no more effective than placebo in HIV-infected children 2
- In HIV-infected adults: 63-67% response with 14-day course (vs. standard 3 days) 2
- Response only seen in patients with CD4 count >50/µL, not in those with CD4 <50/µL 2
Critical Limitations
FDA Black Box Warning Context
Nitazoxanide has NOT been shown effective for cryptosporidiosis in HIV-infected or immunodeficient patients 1. This is a crucial FDA limitation that must guide prescribing decisions.
Evidence Quality Considerations
The 2004 CDC/NIH/IDSA guidelines [2-2] rate nitazoxanide as:
- BI recommendation for HIV-uninfected children with cryptosporidiosis (good evidence)
- CIII recommendation for HIV-infected children (poor evidence, expert opinion only)
The 2017 IDSA guidelines 7 recommend nitazoxanide for cryptosporidiosis in HIV-uninfected patients and HIV-infected patients only in combination with effective antiretroviral therapy (cART).
Clinical Decision Algorithm
For Giardiasis
- First-line: Nitazoxanide 3-day course (all ages ≥1 year, regardless of HIV status) 7
- Alternative: Tinidazole or metronidazole 7
For Cryptosporidiosis
Immunocompetent patients:
HIV-infected patients:
- Primary treatment: Effective cART (antiretroviral therapy) - immune reconstitution is the most important intervention 2, 7
- Adjunctive therapy: Consider nitazoxanide only if CD4 >50/µL and on effective cART 2, 7
- May require 14-day course (not standard 3 days) and higher doses (1000 mg twice daily in adults) 2
Other immunocompromised patients (transplant, malnutrition):
- Nitazoxanide has limited efficacy 8, 9
- Consider combination therapy (nitazoxanide + azithromycin) based on emerging transplant data 8
- Immune reconstitution remains paramount 7
Important Caveats
Stool examination post-treatment: Some patients with clinical resolution still shed cysts/oocysts 1. Manage based on clinical response, not stool results 1.
Suspension preparation: Reconstituted suspension stable for only 7 days at room temperature 1
Drug interactions: The evidence provided does not detail significant interactions, but always verify with current drug interaction databases.
Resistance concerns: Recent data suggests tinidazole may be more efficacious than nitazoxanide for both giardiasis and blastocystosis in some populations 10, though nitazoxanide remains FDA-approved first-line.